Nicergolin Neuraxpharm (Nicergoline)

Nicergoline is employed as a cerebral vasodilator and nootropic in disorders affecting cerebral blood flow and cognition.

• Cognitive decline: improves cerebral perfusion and may support memory function in patients with age‑related or vascular‑related decline.
• Vascular dementia: helps alleviate symptoms by enhancing blood flow to affected brain regions.
• Cerebrovascular insufficiency: increases cerebral circulation, reducing ischemic episodes.
• Alzheimer’s disease: used as an adjunct to improve cognitive symptoms by promoting neuronal metabolism.

• Nicergoline selectively antagonizes α1A‑adrenergic receptors on cerebral vascular smooth muscle, causing arterial relaxation and increased cerebral blood flow. It also inhibits platelet aggregation, modulates serotonergic pathways, and enhances nitric oxide release, together improving neuronal oxygenation and metabolic activity that support cognitive processes.

Nicergoline may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Headache: mild to moderate intensity.
• Dizziness or vertigo.
• Nausea or gastrointestinal discomfort.
• Flushing or warmth sensation.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Cardiac arrhythmias: irregular heart rhythm.

When prescribing Nicergoline, clinicians should consider several precautionary measures to ensure safe use.

• Assess cardiovascular status: evaluate blood pressure and heart disease before initiation.
• Monitor liver function: periodic liver enzyme testing is advised.
• Use cautiously in renal impairment: adjust therapy based on renal function.
• Avoid in patients with known hypersensitivity to ergot derivatives.
• Review concomitant medications: consider potential interactions with antihypertensives and anticoagulants.
• Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Nicergoline can affect the pharmacodynamics of several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Combined use with potent vasodilators (e.g., nitroglycerin): may cause excessive hypotension.
• Concurrent ergot alkaloids (e.g., ergotamine): risk of additive vasospasm and toxicity.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): increase nicergoline plasma levels.

Moderate Interactions (Monitor Closely)

• Antihypertensive agents (e.g., ACE inhibitors): may enhance blood pressure‑lowering effect.
• Anticoagulants/antiplatelet drugs (e.g., warfarin, aspirin): monitor for bleeding tendency.
• SSRIs or SNRIs: potential additive effect on platelet function.